Department of Orthopaedic, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, China.
Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Cancer Med. 2021 Aug;10(15):5218-5234. doi: 10.1002/cam4.3954. Epub 2021 Jul 15.
The carcinogenic effect of NUP37 has been reported recently in a variety of tumors, but its research in the field of glioma has not been paid attention. The main purpose of this study is to reveal the relationship between NUP37 and prognosis or clinical characteristics of glioma patients.
First, as a retrospective study, this study included thousands of tissue samples based on a variety of public databases and clinicopathological tissues. Second, a series of bioinformatics analysis methods were used to analyze the NUP37 and glioma samples from multiple databases such as the CGGA, TCGA, GEO, HPA, and GEPIA. Third, to analyze the relationship between the expression level of NUP37 in tumor tissues and cells and a variety of clinical prognostic molecular characteristics, whether it can be an independent risk factor leading to poor prognosis in glioma and whether it has clinical diagnostic value; GSEA was used to analyze the cancer-related signaling pathways that may be activated by high expression of NUP37. Fifth, CMap was used to analyze small molecule drugs that may inhibit NUP37 expression. Finally, the meta-analysis of thousands of tissue samples from seven datasets and cell proliferation and migration experiments confirmed that NUP37 has a malignant effect on glioma.
NUP37 is highly expressed in glioma patient tissues and glioma cells, significantly correlates with reduced overall survival, and may serve as an independent prognostic factor with some diagnostic value. Silencing NUP37 suppresses malignant biological behaviors of glioma cells. 4 small molecule drugs that had potential targeting inhibitory effects on NUP37 overexpression.
This study demonstrates for the first time a malignant role of NUP37 in glioma and provides a vision to unravel the complex pathological mechanisms of glioma and a potentially valuable biomarker for implementing individualized diagnosis and treatment of glioma.
NUP37 的致癌作用最近在多种肿瘤中被报道，但在胶质瘤领域的研究尚未受到重视。本研究的主要目的是揭示 NUP37 与胶质瘤患者的预后或临床特征之间的关系。
首先，作为一项回顾性研究，本研究基于多种公共数据库和临床病理组织，纳入了数千份组织样本。其次，利用一系列生物信息学分析方法，对来自 CGGA、TCGA、GEO、HPA 和 GEPIA 等多个数据库的 NUP37 和胶质瘤样本进行分析。第三，分析肿瘤组织和细胞中 NUP37 的表达水平与多种临床预后分子特征的关系，是否可以作为导致胶质瘤预后不良的独立危险因素，以及是否具有临床诊断价值；使用 GSEA 分析 NUP37 高表达可能激活的癌症相关信号通路。第五，使用 CMap 分析可能抑制 NUP37 表达的小分子药物。最后，通过对来自七个数据集的数千份组织样本的荟萃分析和细胞增殖与迁移实验，证实 NUP37 对胶质瘤具有恶性作用。
NUP37 在胶质瘤患者组织和胶质瘤细胞中高表达，与总生存期缩短显著相关，可能作为独立的预后因素，具有一定的诊断价值。沉默 NUP37 抑制了胶质瘤细胞的恶性生物学行为。有 4 种小分子药物可能对 NUP37 过表达具有潜在的靶向抑制作用。
本研究首次证明了 NUP37 在胶质瘤中的恶性作用，为揭示胶质瘤复杂的病理机制提供了新视角，并为实施胶质瘤个体化诊断和治疗提供了有潜在价值的生物标志物。
